clinical trial phase
Item
stages 1 and 2
boolean
C0282459 (UMLS CUI [1])
C1096779 (UMLS CUI [2])
gender
Item
1. men and women
boolean
C0079399 (UMLS CUI [1])
age
Item
2. ages 18 30
boolean
C0001779 (UMLS CUI [1])
volunteers
Item
3. normal volunteers
boolean
C0680274 (UMLS CUI [1])
coronary artery disease
Item
4. no history (or suspicion) of cad
boolean
C1956346 (UMLS CUI [1])
clinical trial phase 3
Item
stage 3
boolean
C1096780 (UMLS CUI [1])
coronary artery disease
Item
1. men and women with known or suspected cad
boolean
C1956346 (UMLS CUI [1])
age
Item
2. ages 18 years and older
boolean
C0001779 (UMLS CUI [1])
clinically indicated coronary angiography
Item
3. scheduled for or undergone clinically indicated coronary angiography within 28 days prior to or following study day 1
boolean
C0085532 (UMLS CUI [1,1])
C1444656 (UMLS CUI [1,2])
diagnostic coronary angiography, spect
Item
1. coronary angiography within 28 days prior to study day 1 and/or spect must have been non-interventional
boolean
C0085532 (UMLS CUI [1])
C0183126 (UMLS CUI [2])
coronary angiography digital images
Item
2. coronary angiography images available in digital format (non cine) for transmission to core laboratory
boolean
C0085532 (UMLS CUI [1,1])
C1322781 (UMLS CUI [1,2])
SPECT
Item
4. scheduled for or undergone spect within 28 days prior to or following study day 1
boolean
C0183126 (UMLS CUI [1])
informed consent
Item
1. unable to provide written informed consent
boolean
C0021430 (UMLS CUI [1])
pregnancy, breast feeding
Item
2. women who are pregnant or lactating
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
hypersensitivity or contraindication
Item
3. known hypersensitivity or known contraindication to:
boolean
C0020517 (UMLS CUI [1])
C1301624 (UMLS CUI [2])
dipyridamole contraindication
Item
1. dipyridamole
boolean
C1301624 (UMLS CUI [1,1])
C0012582 (UMLS CUI [1,2])
ultrasound contrast agent contraindication
Item
2. ultrasound contrast agents (including pb127 and excipients)
boolean
C2917331 (UMLS CUI [1,1])
C1301624 (UMLS CUI [1,2])
blood product, albumin or protein contraindication
Item
3. blood, blood products, albumin, egg whites, or protein
boolean
C0456388 (UMLS CUI [1,1])
C1301624 (UMLS CUI [1,2])
C0001924 (UMLS CUI [2,1])
C1301624 (UMLS CUI [2,2])
C0033684 (UMLS CUI [3,1])
C1301624 (UMLS CUI [3,2])
caffeine, xanthine
Item
4. use of caffeine or xanthine containing products within the 24 hours prior to pb127 administration on study day 1 (stages 2 and 3)
boolean
C0006644 (UMLS CUI [1])
C0043314 (UMLS CUI [2])
pb127 exposure
Item
5. previous exposure to pb127
boolean
C0009924 (UMLS CUI [1,1])
C0023175 (UMLS CUI [1,2])
C0332157 (UMLS CUI [1,3])
inadequate echocardiographic windows
Item
6. inadequate echocardiographic windows
boolean
C0013516 (UMLS CUI [1])
heart transplant
Item
7. heart transplant
boolean
C0018823 (UMLS CUI [1])
right to left shunt, atrial septal defect
Item
8. known right to left shunt, including atrial septal defect
boolean
C0428871 (UMLS CUI [1,1])
C0018817 (UMLS CUI [1,2])
cabg
Item
9. history of cabg
boolean
C0010055 (UMLS CUI [1])
ventricular tachycardia, atrial fibrillation, atrial tachycardia, atrial flutter
Item
10. current uncontrolled ventricular tachycardia, atrial fibrillation, atrial tachycardia, or atrial flutter
boolean
C0042514 (UMLS CUI [1])
C0004238 (UMLS CUI [2])
C0546959 (UMLS CUI [3])
C0004239 (UMLS CUI [4])
pacemaker or defibrillator
Item
11. pacemaker or defibrillator
boolean
C0030163 (UMLS CUI [1])
C0180307 (UMLS CUI [2])
unstable angina ccs class grade, symptomatic, iv nitroglycerin infusion
Item
12. unstable angina grade ccs class iv severity with ongoing symptoms and/or ongoing infusion of iv nitroglycerin
boolean
C0002965 (UMLS CUI [1,1])
C1879987 (UMLS CUI [1,2])
C0231220 (UMLS CUI [1,3])
C0017887 (UMLS CUI [1,4])
C0021440 (UMLS CUI [1,5])
heart block
Item
13. second degree or greater heart block
boolean
C0018794 (UMLS CUI [1])
hypertension
Item
14. hypertension (spb >200 and/or dbp >110 mmhg on two consecutive readings within 1 hour prior to pb127 administration)
boolean
C0020538 (UMLS CUI [1])
hypotension
Item
15. hypotension (spb <90 mmhg on two consecutive readings within 1 hour prior to pb127 administration)
boolean
C0020649 (UMLS CUI [1])
aortic stenosis, transvalvular pressure gradient, aortic valve area
Item
16. severe aortic stenosis (>100 mmhg peak transvalvar gradient or <0.6 cm2 estimated valve area)
boolean
C0003507 (UMLS CUI [1,1])
C3854450 (UMLS CUI [1,2])
C0428817 (UMLS CUI [1,3])
pulmonary edema
Item
17. pulmonary edema within the 7 days prior to study day 1
boolean
C0034063 (UMLS CUI [1])
resting oxygen saturation
Item
18. resting oxygen saturation of less than 90%
boolean
C0523807 (UMLS CUI [1,1])
C0035253 (UMLS CUI [1,2])
q wave surgery
Item
19. q wave mi or major surgery within the 7 days prior to study day 1
boolean
C1305738 (UMLS CUI [1,1])
C0543467 (UMLS CUI [1,2])
ptca
Item
20. ptca within the 28 days prior to study day 1
boolean
C2936173 (UMLS CUI [1])
dipyridamole contraindication, copd, bronchospasm
Item
21. chronic obstructive pulmonary disease or bronchospastic airway disease which, in the opinion of the investigator, is significant enough to contraindicate dipyridamole
boolean
C0012582 (UMLS CUI [1,1])
C1301624 (UMLS CUI [1,2])
C0024117 (UMLS CUI [1,3])
C0006266 (UMLS CUI [1,4])
pulmonary hypertension, pulmonary artery systolic pressure
Item
22. known history of severe pulmonary hypertension characterized by estimated pulmonary artery systolic pressure of >50 mmhg
boolean
C0020542 (UMLS CUI [1,1])
C0428643 (UMLS CUI [1,2])
liver disease
Item
23. liver disease, characterized by or including one or more of the following
boolean
C0023895 (UMLS CUI [1])
bilirubin
Item
1. elevated total bilirubin > upper limit of normal
boolean
C1278039 (UMLS CUI [1])
liver enzymes
Item
2. currently elevated hepatic enzymes >3x upper limit of normal
boolean
C1287351 (UMLS CUI [1])
medical condition
Item
24. medical conditions or other circumstances that would significantly decrease the chances of obtaining reliable data or achieving the study objectives (i.e., drug dependence, psychiatric disorder, dementia, or associated illness); extenuating circumstances or medical conditions that make it unlikely that a patient can complete the clinical trial or follow up evaluations; or other reasons for expected poor compliance with the clinical investigator's instructions
boolean
C1699700 (UMLS CUI [1])
C0012634 (UMLS CUI [2])